首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NTF4 |
| Uniprot No | P34130 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 81-210aa |
| 氨基酸序列 | GVSETAPASRRGELAVCDAVSGWVTDRRTAVDLRGREVEVLGEVPAAGGSPLRQYFFETRCKADNAEEGGPGAGGGGCRGVDRRHWVSECKAKQSYVRALTADAQGRVGWRWIRIDTACVCTLLSRTGRA |
| 预测分子量 | 18.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NTF4(Neurotrophin-4)重组蛋白研究的参考文献示例：
1. **"High-yield production of recombinant human Neurotrophin-4 using a mammalian expression system"**
*作者：Zhang et al.*
**摘要**：研究通过哺乳动物细胞表达系统(如HEK293)高效制备重组人NTF4蛋白，优化了表达条件并验证了蛋白的生物活性，证明其能有效激活TrkB受体通路。
2. **"Purification and functional characterization of NTF4 recombinant protein from insect cells"**
*作者：Müller et al.*
**摘要**：利用杆状病毒-昆虫细胞系统表达NTF4.通过亲和层析纯化获得高纯度蛋白，并在体外实验中证实其促进神经元轴突生长的能力。
3. **"Structural insights into NTF4 receptor binding through crystallography"**
*作者：Wang and Sato*
**摘要**：通过X射线晶体学解析了重组NTF4与p75神经营养因子受体的复合物结构，揭示了关键结合域，为设计靶向神经疾病的NTF4类似物提供依据。
4. **"Recombinant NTF4 mitigates neurodegeneration in a rodent model of Parkinson’s disease"**
*作者：Garcia-Ramirez et al.*
**摘要**：在小鼠帕金森模型中，重组NTF4通过脑内注射显著减少多巴胺能神经元死亡，并改善运动功能，提示其治疗神经退行性疾病的潜力。
---
注：以上文献为示例，实际引用需根据具体研究检索真实发表的论文。
**Background of NTF4 Recombinant Protein**
Neurotrophin-4 (NTF4), also known as NT-4 or NT-4/5. is a member of the neurotrophin family of growth factors, which includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3). Discovered in the early 1990s, NTF4 plays a critical role in the development, maintenance, and survival of specific neuronal populations, particularly in the peripheral and central nervous systems. It binds to the tropomyosin receptor kinase B (TrkB) and the p75 neurotrophin receptor (p75NTR), activating downstream signaling pathways that regulate cell survival, differentiation, and synaptic plasticity.
Recombinant NTF4 is produced using genetic engineering techniques, often expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. Its production enables controlled study of neurotrophic mechanisms and therapeutic potential. NTF4 has garnered interest for its neuroprotective properties, with preclinical studies suggesting benefits in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as in nerve injury repair.
Notably, NTF4 has been linked to retinal ganglion cell survival, making it a candidate for treating glaucoma and optic neuropathies. Unlike BDNF, which shows broader expression, NTF4 exhibits more selective effects, potentially reducing off-target risks in therapy. Challenges remain in optimizing delivery methods and stability *in vivo*, but advances in recombinant protein engineering, such as fusion proteins or nanoparticle encapsulation, aim to enhance its clinical applicability.
Research on NTF4 continues to explore its interplay with other neurotrophins and its role in non-neuronal tissues, including immune modulation. As a recombinant tool, it provides insights into neurotrophic signaling and holds promise for developing targeted therapies for neurological and ocular disorders.
×
